Is Alector (Alec) a good stock to buy?

The average of price targets set by Wall Street analysts indicates a potential upside of 142.5% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Who owns Alector Inc?

The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA. ALEC | Complete Alector Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

What does Alector do?

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies.